FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092669111> ?p ?o ?g. }

• W3092669111 endingPage "4364" @default.
• W3092669111 startingPage "4364" @default.
• W3092669111 abstract "Abstract Background: Immunoglobulin light chain amyloidosis (ALA) is a plasma cell dyscrasia that develops, similarly as multiple myeloma (MM), from clinically indistinguishable precancerous stage, monoclonal gammopathy of undetermined significance (MGUS). The specific mutations causing malignant transformation from MGUS to amyloidogenic immunoglobulin producing ALA are still unknown. The next generation sequencing (NGS) technology is a powerful tool that allows comprehensive description of the whole genome sequence. Previous studies have already shown highly overlapping phenotypic profile between ALA and both MGUS and MM and lack of unifying mutations in ALA patients (Paiva, 2016). Here we present whole exome NGS data of aberrant plasma cells (aPCs) obtained from patients with MGUS (n=10) and ALA (n=9). Further comparison of the exome sequences of the precancerosis and malignant stage will help to identify recurrently occurring mutations, novel oncogenic drivers and tumor suppressor genes. This will offer new prognostic markers to distinguish potential malignant plasma cell clones in MGUS that will ultimately lead to the development of fatal ALA. Aims: Revealing the mutational status of aPCs in MGUS and ALA using the whole exome NGS. Material and methods: aPCs and peripheral blood (to exclude germinal mutations) were collected from 9 ALA and 10 MGUS samples. aPCs were separated using fluorescence activated cell sorting and genomic DNA was isolated using AllPrep DNA/RNA Micro Kit (Qiagen) and amplified with REPLI-g Mini (Qiagen). DNA library was prepared using SureSelect Human All Exon V5 Kit and sequenced on Illumina HiSeq 4000 platform with average coverage 50x. Somatic variants were called against human genome version 38 using VarScan v2.0. Only non-synonymous mutations, indels and splice site alterations were considered for further investigation. Results: Using NGS we describe whole exome profile for 9 ALA and 10 MGUS patients. Total number of mutated genes for ALA was 554 (average 69 SNVs per patient) and for MGUS 558 (average 73 SNVs per patient). The number of shared mutated genes between both groups was only 26. Among these genes, we identified 4 functional groups: A) Killer-Cell Immunoglobulin Like Receptors (KIR2DL1, KIR3DL2), B) Mucins (MUC16, MUC3A, MUC6), C) Poly(A) Binding Cytoplasmic Proteins (PABPC1, PABPC3) and D) Serine Proteases (PRSS1, PRSS2, PRSS3). Genetic profiles in ALA and MGUS did not reveal any already known MM driver mutations (KRAS, NRAS, BRAF, FAM46C, TP53 and DIS3), with the exception of one ALA patient possessing mutated DIS3 gene. Importantly, we have observed a significant heterogeneity between the samples, as the number of mutated genes shared by all MGUS or ALA patients was only 7 and 3 genes, respectively. Conclusions: ALA develops from a precancerous stage MGUS. Whole exome sequencing of the aPCs showed comparable number of mutated genes between both disease stages (554 vs. 558). Nevertheless, the mutated genes in both groups were very distinct. We identified only 26 mutated genes shared in both ALA and MGUS. Interestingly, none of these genes was previously linked to tumorigenesis. Moreover, genetic profiles were very heterogeneous among individual patients. Future analysis of the presented data will include comparison with genomic profiles obtained from MM plasma cells to reveal additional insights into the mechanisms of clonal plasma cells development in monoclonal gammopathies. Acknowledgment: This work was supported by the Ministry of Health (15-29667A; DRO - FNOs/2014, DRO - FNOs/2016) and the Ministry of Education, Youth and Sports (Institutional Development Plan of University of Ostrava-IRP201550). Disclosures Hajek: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Novartis: Consultancy, Research Funding; Pharma MAR: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Research Funding." @default.
• W3092669111 created "2020-10-22" @default.
• W3092669111 creator A5008126185 @default.
• W3092669111 creator A5009969874 @default.
• W3092669111 creator A5010121560 @default.
• W3092669111 creator A5012247336 @default.
• W3092669111 creator A5015315146 @default.
• W3092669111 creator A5035166463 @default.
• W3092669111 creator A5039402772 @default.
• W3092669111 creator A5062322697 @default.
• W3092669111 creator A5063903627 @default.
• W3092669111 creator A5069498491 @default.
• W3092669111 creator A5074808789 @default.
• W3092669111 creator A5078353739 @default.
• W3092669111 creator A5083043172 @default.
• W3092669111 creator A5090512266 @default.
• W3092669111 date "2017-12-07" @default.
• W3092669111 modified "2023-10-17" @default.
• W3092669111 title "Whole Exome Sequencing of Plasma Cells Precancerosis MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes" @default.
• W3092669111 doi "https://doi.org/10.1182/blood.v130.suppl_1.4364.4364" @default.
• W3092669111 hasPublicationYear "2017" @default.
• W3092669111 type Work @default.
• W3092669111 sameAs 3092669111 @default.
• W3092669111 citedByCount "0" @default.
• W3092669111 crossrefType "journal-article" @default.
• W3092669111 hasAuthorship W3092669111A5008126185 @default.
• W3092669111 hasAuthorship W3092669111A5009969874 @default.
• W3092669111 hasAuthorship W3092669111A5010121560 @default.
• W3092669111 hasAuthorship W3092669111A5012247336 @default.
• W3092669111 hasAuthorship W3092669111A5015315146 @default.
• W3092669111 hasAuthorship W3092669111A5035166463 @default.
• W3092669111 hasAuthorship W3092669111A5039402772 @default.
• W3092669111 hasAuthorship W3092669111A5062322697 @default.
• W3092669111 hasAuthorship W3092669111A5063903627 @default.
• W3092669111 hasAuthorship W3092669111A5069498491 @default.
• W3092669111 hasAuthorship W3092669111A5074808789 @default.
• W3092669111 hasAuthorship W3092669111A5078353739 @default.
• W3092669111 hasAuthorship W3092669111A5083043172 @default.
• W3092669111 hasAuthorship W3092669111A5090512266 @default.
• W3092669111 hasConcept C104317684 @default.
• W3092669111 hasConcept C10590036 @default.
• W3092669111 hasConcept C159654299 @default.
• W3092669111 hasConcept C163864487 @default.
• W3092669111 hasConcept C16671776 @default.
• W3092669111 hasConcept C17757408 @default.
• W3092669111 hasConcept C203014093 @default.
• W3092669111 hasConcept C2776364478 @default.
• W3092669111 hasConcept C2777250017 @default.
• W3092669111 hasConcept C2780411336 @default.
• W3092669111 hasConcept C36394416 @default.
• W3092669111 hasConcept C36823959 @default.
• W3092669111 hasConcept C501734568 @default.
• W3092669111 hasConcept C502942594 @default.
• W3092669111 hasConcept C51679486 @default.
• W3092669111 hasConcept C542903549 @default.
• W3092669111 hasConcept C54355233 @default.
• W3092669111 hasConcept C86803240 @default.
• W3092669111 hasConceptScore W3092669111C104317684 @default.
• W3092669111 hasConceptScore W3092669111C10590036 @default.
• W3092669111 hasConceptScore W3092669111C159654299 @default.
• W3092669111 hasConceptScore W3092669111C163864487 @default.
• W3092669111 hasConceptScore W3092669111C16671776 @default.
• W3092669111 hasConceptScore W3092669111C17757408 @default.
• W3092669111 hasConceptScore W3092669111C203014093 @default.
• W3092669111 hasConceptScore W3092669111C2776364478 @default.
• W3092669111 hasConceptScore W3092669111C2777250017 @default.
• W3092669111 hasConceptScore W3092669111C2780411336 @default.
• W3092669111 hasConceptScore W3092669111C36394416 @default.
• W3092669111 hasConceptScore W3092669111C36823959 @default.
• W3092669111 hasConceptScore W3092669111C501734568 @default.
• W3092669111 hasConceptScore W3092669111C502942594 @default.
• W3092669111 hasConceptScore W3092669111C51679486 @default.
• W3092669111 hasConceptScore W3092669111C542903549 @default.
• W3092669111 hasConceptScore W3092669111C54355233 @default.
• W3092669111 hasConceptScore W3092669111C86803240 @default.
• W3092669111 hasLocation W30926691111 @default.
• W3092669111 hasOpenAccess W3092669111 @default.
• W3092669111 hasPrimaryLocation W30926691111 @default.
• W3092669111 hasRelatedWork W1978030902 @default.
• W3092669111 hasRelatedWork W2024040061 @default.
• W3092669111 hasRelatedWork W2224927009 @default.
• W3092669111 hasRelatedWork W2291974750 @default.
• W3092669111 hasRelatedWork W2506095344 @default.
• W3092669111 hasRelatedWork W2518941786 @default.
• W3092669111 hasRelatedWork W2530506542 @default.
• W3092669111 hasRelatedWork W2538734709 @default.
• W3092669111 hasRelatedWork W2539796224 @default.
• W3092669111 hasRelatedWork W2557109348 @default.
• W3092669111 hasRelatedWork W2576356661 @default.
• W3092669111 hasRelatedWork W2581848256 @default.
• W3092669111 hasRelatedWork W2584724954 @default.
• W3092669111 hasRelatedWork W277760747 @default.
• W3092669111 hasRelatedWork W2910178265 @default.
• W3092669111 hasRelatedWork W2980311311 @default.
• W3092669111 hasRelatedWork W2987386752 @default.
• W3092669111 hasRelatedWork W2992342257 @default.
• W3092669111 hasRelatedWork W3000443883 @default.
• W3092669111 hasRelatedWork W3015583817 @default.

• next